FDA Approves Kamada's San Antonio Plasma Center, Projecting $8M-$10M Annual Revenue
KMDA sits 49% above its 52-week low of $5.54.
Summary
Kamada announced that the FDA has approved its new plasma collection center in San Antonio, Texas, following a successful inspection in February. This approval enables the facility, designed for approximately 50,000 liters of plasma collection annually, to begin commercial sales of normal source plasma. The company expects this center to generate $8 million to $10 million in annual revenues at full capacity, representing a material addition to its operational capacity and revenue streams. This regulatory clearance is a positive step for Kamada, enhancing its plasma supply chain and supporting its growth strategy in specialty plasma-derived therapies.
At the time of this announcement, KMDA was trading at $8.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $473M. The 52-week trading range was $5.54 to $9.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.